NCT06982729View on ClinicalTrials.gov

Study of YK012 in Primary Membranous Nephropathy

PHASE1RecruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

March 8, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Primary Membranous Nephropathy
Interventions
DRUG

YK012

YK012 is a bispecific antibody targeting CD19 on B cells and CD3 on T cells leading to T cell-mediated cytotoxicity of malignant B cells

Trial Locations (1)

100034

RECRUITING

Peking University First Hospital, Beijing

Sponsors
All Listed Sponsors
lead

Excyte Biopharma Ltd

INDUSTRY